Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia

Arthritis Care and Research

Volumn 64, Issue 8, 2012, Pages 1202-1208

  Ste Marie, Peter A ^a   Fitzcharles, Mary Ann ^a   Gamsa, Ann ^b   Ware, Mark A ^b   Shir, Yoram ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABIS; OPIATE;

ADULT; ANALGESIA; ARTICLE; DISABILITY; DRUG SEEKING BEHAVIOR; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRESCRIPTION; SEX DIFFERENCE;

ADULT; CANNABINOIDS; CANNABIS; CHRONIC PAIN; COHORT STUDIES; FEMALE; FIBROMYALGIA; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; PREVALENCE; PSYCHOLOGY; RETROSPECTIVE STUDIES; SELF MEDICATION;

EID: 84864492845     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21732     Document Type: Article

References (38)

1. Pertwee RG,. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147 Suppl: S163-71.
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
3. McNally JD, Matheson DA, Bakowsky VS,. The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can 2006; 27: 9-16.
4. Boomershine CS, Crofford LJ,. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol 2009; 5: 191-9.
5. Boisset M, Fitzcharles MA,. Alternative medicine use by rheumatology patients in a universal health care setting. J Rheumatol 1994; 21: 148-52.
6. Lynch ME, Campbell F,. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol 2011; 72: 735-44.
7. Manzanares J, Julian MD, Carrascosa A,. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 2006; 4: 239-57.
8. Fitzcharles MA, Ste-Marie PA, Gamsa A, Ware MA, Shir Y,. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med 2011; 124: 955-60.
9. Burckhardt CS, Clark SR, Bennett RM,. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991; 18: 728-33.
10. Portenoy RK,. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996; 11: 203-17.
11. Cravatt BF, Lichtman AH,. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 2004; 61: 149-60.
12. Burstein SH, Zurier RB,. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 2009; 11: 109-19.
13. Pertwee RG,. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
14. Downer EJ,. Cannabinoids and innate immunity: taking a toll on neuroinflammation. ScientificWorldJournal 2011; 11: 855-65.
15. Shimizu T,. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009; 49: 123-50.
16. Erkens JA, Janse AF, Herings RM,. Limited use of medicinal cannabis but for labeled indications after legalization. Pharmacoepidemiol Drug Saf 2005; 14: 821-2.
17. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. 2010. URL:.
18. Tu AW, Ratner PA, Johnson JL,. Gender differences in the correlates of adolescents' cannabis use. Subst Use Misuse 2008; 43: 1438-63.
19. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME,. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004; 62: 2098-100.
20. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ,. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003; 102: 211-6.
21. Health Canada. Marihuana for medical purposes: statistics. 2010. URL:.
22. Bronstein K, Dhaliwal J, Leider H,. Rates of inappropriate drug use in the chronic pain population: an update. J Pain 2011; 12: P5.
23. Swift W, Gates P, Dillon P,. Survey of Australians using cannabis for medical purposes. Harm Reduct J 2005; 2: 18.
24. Ware MA, Adams H, Guy GW,. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005; 59: 291-5.
25. Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009; 36: 2318-29.
26. Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R,. Δ-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006; 22: 1269-76.
27. Ware MA, Fitzcharles MA, Joseph L, Shir Y,. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110: 604-10.
28. Skrabek RQ, Galimova L, Ethans K, Perry D,. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9: 164-73.
29. Fiz J, Duran M, Capella D, Carbonell J, Farre M,. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One 2011; 6: e18440.
30. Fitzcharles MA, Boulos P,. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology (Oxford) 2003; 42: 263-7.
31. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD,. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007; 8: 573-82.
32. Cichewicz DL,. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74: 1317-24.
33. Wang T, Collet JP, Shapiro S, Ware MA,. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008; 178: 1669-78.
34. Ware MA, Tawfik VL,. Safety issues concerning the medical use of cannabis and cannabinoids. Pain Res Manag 2005; 10 Suppl: 31A-7A.
35. Kalant H,. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 849-63.
36. Ware MA, St Arnaud-Trempe E,. The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010; 105: 494-503.
37. Calhoun SR, Galloway GP, Smith DE,. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 1998; 30: 187-96.
38. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ,. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-6.